Avastin’s revenue trends
Roche’s (RHHBY) Avastin generated revenues of 3.42 billion Swiss francs in the first half. Avastin revenues in the first half remained flat compared to the first half of 2017.
In the first half, in the United States, Europe, and Japan, Avastin generated revenues of 1.4 billion Swiss francs, 933.0 million Swiss francs, and 404.0 million Swiss francs, respectively. This compared with 1.5 billion Swiss francs, 881.0 million Swiss francs, and 390.0 million Swiss francs in the first half of 2017. In both the United States and European markets, Avastin witnessed an ~2.0% YoY (year-over-year) decline in constant currency rates (or CER).
In the second quarter, Avastin reported revenues of 1.8 billion Swiss francs, which reflected ~1.0% YoY growth at CER. The increased competition from the immunotherapy drugs for lung cancer primarily led to the decline of Avastin revenues in the United States in the first half.
In June, the FDA approved Avastin in combination with chemotherapy followed by Avastin monotherapy. This therapy is intended to treat women with advanced ovarian cancer after primary surgical resection. The FDA approved Avastin for this indication based on the data from the pivotal phase 3 GOG-0218 trial.
In the phase 3 GOG trial, women administered with chemotherapy followed by Avastin monotherapy demonstrated median PFS (progression-free survival) of 18.2 months. Women who were administered only chemotherapy demonstrated median PFS of 12.0 months.
The superior efficacy data could strengthen Avastin’s commercialization capabilities. The approval of label expansion of Avastin by the FDA could boost the revenue growth of the drug in 2018.